These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 15061384)

  • 1. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
    Topić E; Stefanović M; Samardzija M
    Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First report of warfarin dose requirements in patients possessing the CYP2C9*12 allele.
    O'Brien TJ; Kidd RS; Richard CA; Ha NH; Witcher P; Tran LV; Barbour A; Tuck M; McIntosh SD; Douglas JN; Harralson AF
    Clin Chim Acta; 2013 Sep; 424():73-5. PubMed ID: 23688605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
    Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
    Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin dosing and cytochrome P450 2C9 polymorphisms.
    Joffe HV; Xu R; Johnson FB; Longtine J; Kucher N; Goldhaber SZ
    Thromb Haemost; 2004 Jun; 91(6):1123-8. PubMed ID: 15175798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
    Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
    Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytochrome P4502C9(CYP2C9) gene polymorphism and safety of therapy with warfarin].
    Mikheeva IuA; Kropacheva ES; Ignat'ev IV; Bulytova IuM; Ramenskaia GV; Sychev DA; Dobrovol'skiĭ AB; Panchenko EP
    Kardiologiia; 2008; 48(3):52-7. PubMed ID: 18429757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytochrome P450 2C9 polymorphisms (CYP2C9) and warfarin maintenance dose in elderly patients].
    Siguret V; Gouin I; Golmard JL; Geoffroy S; Andreux JP; Pautas E
    Rev Med Interne; 2004 Apr; 25(4):271-4. PubMed ID: 15050794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of CYP2C9 genotypes among Omani patients receiving warfarin and its correlation with warfarin dose.
    Tanira MO; Al-Mukhaini MK; Al-Hinai AT; Al Balushi KA; Ahmed IS
    Community Genet; 2007; 10(1):32-7. PubMed ID: 17167248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9.
    Loebstein R; Vecsler M; Kurnik D; Austerweil N; Gak E; Halkin H; Almog S
    Clin Pharmacol Ther; 2005 May; 77(5):365-72. PubMed ID: 15900282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
    Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
    Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
    King BP; Khan TI; Aithal GP; Kamali F; Daly AK
    Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes.
    Takahashi H; Kashima T; Nomizo Y; Muramoto N; Shimizu T; Nasu K; Kubota T; Kimura S; Echizen H
    Clin Pharmacol Ther; 1998 May; 63(5):519-28. PubMed ID: 9630825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytochrome P450 2C9 gene polymorphism and warfarin maintenance dosage in pediatric patients: A systematic review and meta-analysis.
    Zhang J; Tian L; Huang J; Huang S; Chai T; Shen J
    Cardiovasc Ther; 2017 Feb; 35(1):26-32. PubMed ID: 27661060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
    Siddiqi A; Khan DA; Khan FA; Naveed AK
    Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.
    Higashi MK; Veenstra DL; Kondo LM; Wittkowsky AK; Srinouanprachanh SL; Farin FM; Rettie AE
    JAMA; 2002 Apr; 287(13):1690-8. PubMed ID: 11926893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variability in CYP2C9 allele frequency: a pilot study of its predicted impact on warfarin response among healthy South and North Indians.
    Nahar R; Deb R; Saxena R; Puri RD; Verma IC
    Pharmacol Rep; 2013; 65(1):187-94. PubMed ID: 23563037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
    Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin.
    Gage BF; Eby C; Milligan PE; Banet GA; Duncan JR; McLeod HL
    Thromb Haemost; 2004 Jan; 91(1):87-94. PubMed ID: 14691573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Warfarin dose related to apolipoprotein E (APOE) genotype.
    Kohnke H; Sörlin K; Granath G; Wadelius M
    Eur J Clin Pharmacol; 2005 Jul; 61(5-6):381-8. PubMed ID: 15952022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
    Aithal GP; Day CP; Kesteven PJ; Daly AK
    Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.